

Standing Order for Dispensing and Administration of COVID-19 Vaccine: 2025-2026

This standing order authorizes qualified pharmacy personnel pursuant to 105 CMR 700.004(B)(6) to dispense and administer COVID-19 vaccine in Massachusetts to all eligible persons as described below.

Procedure

- 1) Assess for Need of Vaccination.
- 2) Screen for Contraindications and Precautions.
Contraindications:
 - A severe allergic reaction (e.g., anaphylaxis) after a previous dose of the COVID-19 vaccine or to a component of the COVID-19 vaccinePrecautions:
 - A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
 - Non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.
 - Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
 - Moderate to severe acute illness, with or without fever.
- 3) Provide Vaccine Information Statements.
- 4) Prepare to Administer Vaccine.
 - Verify that the label on the vaccine states 2025-2026 Formula.
 - Choose the needle gauge, needle length, and injection site.
- 5) Administer COVID-19 Vaccine

For intramuscular administration

- MNEXSPIKE (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
Dispense single 0.2 mL dose for:
 - Individuals 12 years of age and older
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of MNEXSPIKE at least 3 months after the last dose of COVID-19 vaccineDirections for use: Administer MNEXSPIKE as a single 0.2 mL dose

OR

- SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 5 years of age through 11 years of age
Dispense single 0.25 mL dose, irrespective of COVID-19 vaccination status.
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2 months after the last dose of COVID-19 vaccineDirection for use: Administer SPIKEVAX 0.25 mL dose
 - OR**
 - b. Individuals 12 years of age and older
Dispense single 0.5 mL dose, irrespective of COVID-19 vaccination status.
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2 months after the last dose of COVID-19 vaccineDirection for use: Administer SPIKEVAX 0.5 mL dose

OR

- COMIRNATY (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 5 years of age through 11 years of age
Dispense single 0.3 mL dose supplied in vials with blue caps and labeled with blue borders
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccineDirections for use: Administer COMIRNATY as a single 0.3 mL dose
OR
 - b. Individuals 12 years of age and older
Dispense single 0.3 mL dose supplied in prefilled syringes labeled with gray borders
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccineDirection for use: Administer COMIRNATY as a single 0.3 mL dose

OR

- NUVAXOVID (COVID-19 Vaccine, Adjuvanted) injectable suspension, 2025-2026 Formula
Dispense single 0.5 mL dose for:
 - Individuals 12 years of age and older
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of NUVAXOVID at least 2 months after the last dose of COVID-19 vaccineDirections for use: Administer NUVAXOVID as a single 0.5 mL dose

- 6) Document the Vaccination.
- 7) Be Prepared to Manage Medical Emergencies.
- 8) Report Adverse Events to the Vaccine Adverse Event Reporting System (VAERS).


Physician's Signature

August 29, 2025

Robert H Goldstein, MD, PhD

MA 261463

Physician's Name and MA License No. (print legibly)